Log In
BCIQ
Print this Print this
 

ASN004

  Manage Alerts
Collapse Summary General Information
Company Asana BioSciences LLC
DescriptionAntibody-drug conjugate formulated using Mersana Therapeutics Inc.'s Dolaflexin platform targeting oncofetal antigen 5T4
Molecular Target Oncofetal antigen 5T4
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today